U.S. flag
        An official website of the United States government
          Here’s how you know

      Official websites use .gov
                A
                .gov
                website belongs to an official government organization in the United States.
          Secure .gov websites use HTTPS
                A lock
                  (
                  
                  )
                   or
                  https://
                   means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.Search
                Menu
    
                      Información en Español
                      Search NINDSSearch NINDS
            

            Main navigation
  

        
              Health Information
                                     Toggle Health Information Dropdown
                                Disorders
                Clinical Trials
                Patient & Caregiver Education
                Public Education
                Support Resources
                Funding
                                     Toggle Funding Dropdown
                                Find Funding Opportunities
                About Funding
                Preparing Your Application
                After You Submit
                Determining Your Funding Likelihood
                Manage Your Award
                NINDS Small Business Program
                Training & Career Development
                Current Research
                                     Toggle Current Research Dropdown
                                Coronavirus and NINDS
                Focus on Disorders
                Focus on Tools & Topics
                Research Funded by NINDS
                Research at NINDS
                Scientific Resources
                Trans-Agency Activities
                News & Events
                                     Toggle News & Events Dropdown
                                Events
                News
                Director's Messages
                About NINDS
                                     Toggle About NINDS Dropdown
                                Who We Are
                What We Do
                Job Opportunities 
 Home
                                About NINDS
                        What We Do
                        Budget & Legislation
                        NINDS Annual Budget
SHARE: NINDS 2024 Congressional Budget Justification
General Notes

FY 2023 Enacted levels cited in this document include the effects of the FY 2023 HIV/AIDS transfer, as shown in the Amounts Available for Obligation table.
	Detail in this document may not sum to the subtotals and totals due to rounding.

Director's Overview

Image
              Photo of NINDS Director, Dr. Walter Koroshetz
Walter J. Koroshetz, M.D., DirectorThe mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people. The complexity of the brain and nervous system and the substantial collective burden of neurological disorders combine to make this mission a formidable challenge. Our success depends on supporting and conducting rigorous and innovative research that leverages knowledge and tools from multiple scientific disciplines. Just as importantly, ensuring that this research ultimately benefits all people depends on our ability to harness diverse perspectives from an inclusive research workforce and from patients and communities who are directly affected by neurological disorders. Guided by the NINDS 2021-2026 Strategic Plan, urgent public health needs, and promising scientific opportunities, NINDS is investing in neuroscience research for everyone.



Embracing diversity, equity, inclusion, and accessibility

NINDS has long recognized that all of neuroscience benefits if we can engage all segments of society in our efforts. The NINDS Strategic Plan includes goals to ensure a vibrant, talented, and diverse neuroscience workforce and to create and sustain a supportive work culture, and it emphasizes overall that diversity, equity, inclusion, and accessibility (DEIA) are essential to the way we work to fund, conduct, and support research. Consistent with this plan, we are sharpening our focus on actionable steps to enhance DEIA at NINDS and across the research and patient communities we support. Within NINDS, we established an initiative called Culture of Respect and Engagement through Inclusion, Diversity, Equity, Accessibility, and Leadership Support (CORE IDEALS), and as part of the NIH UNITE Initiative, NINDS has developed a dynamic Racial and Ethnic Equity Plan (REEP) that incorporates data-driven strategies and community input to advance racial and ethnic equity at NINDS. We also take a comprehensive approach to enhancing diversity in the extramural neuroscience workforce across the research career pipeline, and a new program seeks to increase diversity among independent investigators funded through Research Project Grants (R01), the mainstay of NIH support for investigator-initiated research. As a model for elevating attention to diversity across other NIH programs, the NIH Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative® requires most grant proposals to include a Plan for Enhancing Diverse Perspectives (PEDP).1

_______________________________________________

1  Plan for Enhancing Diverse Perspectives (PEDP)

Achieving health equity for neurological disorders

In the United States, the risk of stroke is nearly twice as high for Black people as for White people. Despite overall declines in stroke mortality, Black people have the highest rate of death due to stroke, and Hispanic and American Indian/Alaska Native populations have seen the least improvement over time.2 Hispanic and Black Americans are most at risk for Alzheimer’s disease and related dementias, 3 and the burden of these conditions is expected to increase. The coronavirus disease 2019 (COVID-19) pandemic has accentuated disparities, with less advantaged groups facing greater risks of infection and death, and potentially greater risk for persistent neurological complications. NINDS is committed to understanding and eliminating these and other inequities in the prevalence, health outcomes, and care of neurological disorders, whether associated with different races and ethnicities, religion, socioeconomic status, age, mental health, disability, gender, sexual orientation, gender identity, geographic location, or other characteristics historically linked to discrimination, stigmatization, or exclusion. We are working to address research priorities identified in a new strategic plan for health equity in neurological disorders, with a focus on biologic, sociodemographic, economic, and other determinants of health. For example, two new funding opportunities4 through the NIH Helping to End Addiction Long-term® (HEAL) Initiative aim to support interventions to improve care and outcomes for pain and pain-related comorbidities in populations that experience health disparities. Additional initiatives will support research to test whether lowering vascular risk factors for stroke can also prevent cognitive decline and dementia, especially in racial and ethnic minority groups,5 as well as community-engaged studies to understand how early life social determinants of health (SDOH) and adverse childhood experiences contribute to the development of cognitive impairment and dementia, especially in populations experiencing health disparities.6

_______________________________________________

2  Source: National Vital Statistics Sample 2008-2018 (latest data available as of Oct 2020)

3  Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years

4  RFA-NS-22-002; RFA-NS-22-037

5  RFA-NS-23-001

6  PAR-22-221

Critical public health challenges and targeted interventions

NINDS is actively engaged in research on some of the greatest public health challenges facing our nation. Among these, NINDS works in close partnership with the National Institute on Aging (NIA) to coordinate and support research on Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD), which include frontotemporal degeneration (FTD), Lewy body dementia (LBD), multiple etiology dementias (MED), and vascular contributions to cognitive impairment and dementia (VCID). In 2022, NINDS led the fourth triennial summit on ADRD to identify updated research priorities, with recommendations for FTD, LBD, MED, and VCID. The summit also addressed opportunities to improve health equity for ADRD and the impact of COVID-19 on AD/ADRD risk and outcomes. Since FY 2016, increased funding for AD/ADRD research has allowed NINDS to expand investigator-initiated research, support opportunities in specific priority areas, and establish collaborative programs and consortia, including efforts focused on the early detection of cognitive impairment and dementia; understanding how stroke, other vascular brain changes, and traumatic brain injury (TBI) affect dementia risk; and identifying FTD and LBD mechanisms and biomarkers. This research is yielding important insights, including recognition that many potential paths to neurodegeneration are shared across conditions, which may inform strategies to prevent or slow disease. Recent studies also suggest that blood-based biomarkers for AD/ADRDs are on the horizon, edging closer to a long-held goal to develop non-invasive measures to aid early intervention.

Launched in 2018, the NIH HEAL Initiative® is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. As the primary NIH Institute for pain research, NINDS efforts in the HEAL Initiative focus on developing safe, effective non-addictive pain treatments that may mitigate the need for opioids.7NINDS leads multiple programs within the HEAL Initiative, spanning research supplements to promote research workforce diversity, translational programs for the discovery and development of new treatments, and clinical infrastructure for testing interventions, including the Early Phase Pain Investigation Clinical Network (EPPIC-Net). New therapies are under development and three clinical trials are underway through these NINDS-led programs. In 2022, new awards began through the HEAL Initiative Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). The new network awards support concerted, multidisciplinary team science applying high-throughput analyses to human tissues, with a goal to build comprehensive datasets on molecular and cellular pain signatures that will facilitate the discovery and validation of therapeutic targets.

Given the large and still rising number of Americans affected by COVID-19, research to understand and limit its acute and long-term impacts remains a critical priority. COVID-19-related funding has allowed NINDS intramural and extramural researchers to build knowledge about acute effects of the SARS-CoV-2 virus on the nervous system, as well as persistent, disabling symptoms (Long COVID) lasting weeks or months in some people, such as pain, headaches, fatigue, postural orthostatic tachycardia, sleep disorders, post exertional malaise, and cognitive difficulties. NINDS is also a leading partner in the NIH REsearching COVID to Enhance Recovery (RECOVER) Initiative, established to learn why some people have prolonged symptoms or develop new or returning symptoms after SARS-CoV-2 infection and to inform Long COVID prevention and recovery. Research on Long COVID may shed light on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a poorly understood disorder with no effective treatments. Many people with ME/CFS report its onset after an infectious-like illness, and some symptoms associated with Long COVID overlap with those of ME/CFS.

NINDS basic research, on normal nervous system function and disease mechanisms, is the foundation for discovering new cures and preventive interventions. As research homes in on mechanisms behind individual conditions, the potential for targeted therapies grows. For example, existing treatments for epilepsy can have intolerable side effects and are ineffective for about a third of people with epilepsy. Through the Centers Without Walls for Collaborative Research in the Epilepsies, NINDS supports two teams focused on understanding how individual genetic variants cause different types of epilepsy, which will inform new precision therapies. NINDS supports a suite of milestone-driven translational research initiatives to move therapies from target identification to a point of readiness sufficient for industry interest, or in some cases, for testing through NINDS-supported clinical research networks. As recent examples of success, industry investments will advance further development of therapies for pain and epilepsy that were previously supported through the NIH Blueprint Neurotherapeutics Network and the NIH HEAL Initiative Pain Therapeutics Development Program. Among our newest programs, the NINDS Ultra-Rare Gene Therapy (URGenT) Network will bring gene targeting technologies to the development of disease-modifying therapies for ultra-rare disorders, which present unique challenges for therapy development.

_______________________________________________

7  NINDS' Role in the HEAL Initiative

Engaging the community in progress

To drive meaningful advances, the research NINDS supports and conducts must align with priorities of people with lived experience of neurological disorders. Moreover, ensuring that participation in our research is inclusive and accessible is a critical component of our broader DEIA efforts. Consistent with a cross-cutting strategy in the NINDS Strategic Plan, we are strengthening patient and community engagement in NINDS research and have hired dedicated staff to lead in this area. We are working with research and patient communities in priority setting, including as key contributors in new research strategic plans for amyotrophic lateral sclerosis (ALS) and ME/CFS and a recent workshop on cerebral palsy research. In addition, people affected by ALS served on the review committee for a new initiative to support research using data from expanded access to investigational therapies, a provision of the Accelerating Access to Critical Therapies for ALS (ACT for ALS) Act. Also as part of the ACT for ALS, the NIH and the U.S. Food and Drug Administration (FDA) announced a public-private partnership that will convene the ALS community to develop novel strategies for therapy development and clinical testing with the goal to produce a treatment that stops the progression of ALS.8 More broadly, NINDS is developing standard requirements for clinical research studies to include community engagement plans, and NINDS clinical research networks are building community and patient representation into study development and execution. In NIH-wide programs, the HEAL Initiative has adopted innovative approaches to engage people living with pain conditions in clinical research, and the NIH BRAIN Initiative® Neuroethics Working Group held a meeting on addressing the needs of research participants after study protocols end.

_______________________________________________

8  FDA and NIH Launch Public-Private Partnership for Rare Neurodegenerative Diseases

Tackling the undiscovered through powerful science and creative teams

The complexity of the brain and nervous system continues to challenge and inspire researchers. NINDS is a leader in the NIH BRAIN Initiative®, which is applying innovative technologies to learn how brain circuits work. Building on the program’s successes to date, transformative projects are now underway to develop a comprehensive brain cell atlas, a whole mammalian brain microconnectivity map, and tools for precision access to brain cell types. These large-scale projects will open new doors for exploring the brain and, ultimately, for developing new ways to treat and prevent brain diseases. The BRAIN Initiative, the HEAL Initiative, and other NIH programs are demonstrating the power of interdisciplinary teams to solve scientific challenges, and NINDS has established a new program to apply a team-science approach and build new interdisciplinary synergies within our investigator-initiated research portfolio.

Since 2013, the NIH Undiagnosed Diseases Network (UDN) has helped to diagnose nearly 600 perplexing medical conditions, including over 50 newly identified conditions. NINDS has been an important part of the UDN since its inception, given the large number of rare diseases that affect the nervous system. NINDS will now play a leading role in ensuring that this program transitions successfully from the NIH Common Fund to long-term sustainability, including through support for a data management and coordinating center and transitional funding for clinical sites.9 Moving forward, the UDN plans to broaden participation for under/uninsured participants and health disparity populations, integrate the UDN team approach into clinical care, and incorporate additional sites across the country. Advances in genetic research have accelerated discoveries about what causes neurological diseases. However, much remains unknown about non-inheritable factors, including environmental exposure to toxins, social activity and stress, diet, and the microbiome. The new NINDS Office of Neural Exposome and Toxicology (ONETOX) will collaborate across NIH in this growing research area.

_______________________________________________

9  RFA-NS-22-051; RFA-NS-23-004

IC Fact Sheet

View IC Fact Sheet(pdf, 2055 KB)

Major Changes in the Budget Request

Major changes by budget mechanism and/or budget activity detail are briefly described below. Note that there may be overlap between budget mechanism and activity detail, and these highlights will not sum to the total change for the FY 2024 President’s Budget request for NINDS, which is $2,825.4 million, an increase of $16.0 million from the FY 2023 Enacted level. The request includes $86.0 million provided by the 21st Century Cures Act. Within the President’s Budget request level, NINDS will pursue its highest research priorities through strategic investments and careful stewardship of appropriated funds.

**Research Project Grants (RPGs) (+$27.6 million; total $2,081.9 million):**
The NINDS budget reflects an increase of $27.6 million in the Research Project Grants portfolio, including SBIR/STTR awards. Competing RPGs are expected to increase by 67 grants in FY 2024 compared to the FY 2023 enacted level of awards.

**Research Training (+$2.2 million; total $38.2 million):**NINDS together with the BRAIN Initiative plans to increase the numbers of individual and institutional awards to continue to promote and support the next generation of researchers in neuroscience.

**Research and Development Contracts (+$5.2 million; total $157.1 million):**NINDS plans to increase R&D contract funding to accommodate new and expanded contracts within the Biologics and Blueprint Neurotherapeutics Programs.

**Intramural Research (-$21.8 million; total $239.6 million):**
In FY 2023, a catastrophic flood occurred in the Porter Neuroscience Building, resulting in one-time FY 2023 costs for NINDS to repair damage and restore lost capital equipment and supplies for 18 NINDS laboratories. The FY 2024 request for NINDS intramural research is a reduction from the FY 2023 Enacted level due to phasing out these one-time costs.

**Research Management and Support (+$7.2 million; total $104.9 million):**
As part of the commitment to effective and efficient stewardship across NINDS programs, the budget reflects an increase of $7.2 million in Research Management and Support to secure additional staff and other support to provide appropriate capacity and oversight for the rapid growth of the NINDS and special initiatives grant portfolio.

Budget Mechanism Table

Budget Mechanism - Total 1,2

**(Dollars in Thousands)**

MECHANISM
			FY 2022
			Final3
			FY 2023 Enacted
			FY 2024
			President's Budget
			FY 2024
			+/-
			FY 2023No.
			Amount
			No.
			Amount
			No.
			Amount
			No.
			AmountResearch Projects:Noncompeting
			2,227
			$1,171,496
			2,364
			$1,296,099
			2,637
			$1,435,897
			273
			$139,799Administrative Supplements
			*(261)*
			24,504
			*(260)*
			23,972
			*(265)*
			25,496
			*(5)*
			1,524Competing:Renewal
			110
			60,183
			69
			33,173
			79
			53,196
			10
			20,023New
			853
			559,542
			735
			610,901
			802
			475,588
			67
			-135,312Supplements
			0
			0
			0
			0
			0
			0
			0
			0Subtotal, Competing
			**963**
			**$619,725**
			**804**
			**$644,074**
			**881**
			**$528,784**
			**77**
			**-$115,290**Subtotal, RPGs
			3,190
			$1,815,726
			3,168
			$1,964,144
			3,518
			$1,990,177
			350
			$26,033SBIR/STTR
			115
			82,901
			127
			90,130
			126
			91,729
			-1
			1,599Research Project Grants
			3,305
			$1,898,626
			3,295
			$2,054,274
			3,644
			$2,081,906
			349
			$27,632Research Centers:Specialized/Comprehensive
			25
			$31,574
			26
			$32,082
			26
			$32,200
			0
			$118Clinical Research
			0
			0
			0
			0
			0
			0
			0
			0Biotechnology
			0
			0
			0
			0
			0
			0
			0
			0Comparative Medicine
			0
			237
			0
			137
			0
			0
			0
			0Research Centers in Minority Institutions
			0
			0
			0
			0
			0
			0
			0
			-137Research Centers
			**25**
			**$31,811**
			**26**
			**$32,220**
			**26**
			**$32,200**
			**0**
			**-$20**Other Research:Research Careers
			288
			$58,325
			$294
			$58,776
			300
			$60,669
			6
			$1,893Cancer Education
			0
			0
			0
			0
			0
			0
			0
			0Cooperative Clinical Research
			0
			1,948
			9
			2,902
			8
			1,802
			-1
			-1,101Biomedical Research Support
			0
			0
			0
			0
			0
			0
			0
			0Minority Biomedical Research Support
			0
			0
			0
			0
			0
			0
			0
			0Other
			262
			96,296
			282
			114,167
			291
			109,064
			9
			-5,103Other Research
			**550**
			**$156,570**
			**585**
			**$175,845**
			**599**
			**$171,534**
			**14**
			**-$4,310**Total Research Grants
			3,880
			$2,087,007
			3,906
			$2,262,339
			4,269
			$2,285,641
			363
			$23,302Ruth L. Kirschstein Training Awards:
			FTTPs
			
			FTTPs
			
			FTTPsIndividual Awards
			343
			15,250
			392
			$17,869
			397
			$19,494
			5
			$1,625Institutional Awards
			285
			17,517
			290
			18,182
			300
			18,714
			10
			532Total Research Training
			**628**
			**$32,767**
			**682**
			**$36,051**
			**697**
			**$38,208**
			**15**
			**$2,157**Research & Development Contracts
			133
			$157,591
			134
			$151,891
			129
			$157,105
			-5
			$5,213*SBIR/STTR (non-add)*
			*(1)*
			*(1,056)*
			*(3)*
			*(1,089)*
			*(3)*
			*(1,099)*
			*(0)*
			*(10)*Intramural Research
			321
			233,988
			330
			$261,413
			345
			239,569
			15
			-21,844Research Management and Support
			280
			95,837
			302
			97,724
			362
			104,896
			60
			7,172*Res. Management & Support (SBIR Admin) (non-add)*
			*(0)*
			*(732)*
			*(0)*
			*(760)*
			*(0)*
			*(789)*
			*(0)*
			*(29)*Construction
			
			0
			
			0
			
			0
			
			0Buildings and Facilities
			
			0
			
			0
			
			0
			
			0**Total, NINDS**
			**601**
			**$2,607,190**
			**632**
			**$2,809,418**
			**707**
			**$2,825,418**
			**75**
			**$16,000**1 All items in italics and brackets are non-add entries.

2 Of which $76.0 million in FY 2022, $225.0 million in FY 2023, and $86.0 million in FY 2024 is derived by transfer from the NIH Innovation Account under the 21st Century Cures Act.

3 Includes $23.4 million of 21st Century Cures Act funding not obligated in FY 2022 and carried over into FY 2023.

Appropriations Language

For carrying out section 301 and title IV of the PHS Act with respect to neurological disorders and stroke, [$2,588,925,000]*$2,739,418,00*.

**NIH INNOVATION ACCOUNT, CURES ACT (INCLUDING TRANSFER OF FUNDS)**

For necessary expenses to carry out the purposes described in section 1001(b)(4) of the 21st Century Cures Act, in addition to amounts available for such purposes in the appropriations provided to the NIH in this Act, [$1,085,000,000] *$407,000,000*, to remain available until expended: Provided, That such amounts are appropriated pursuant to section 1001(b)(3) of such Act, are to be derived from amounts transferred under section 1001(b)(2)(A) of such Act, and may be transferred by the Director of the National Institutes of Health to other accounts of the National Institutes of Health solely for the purposes provided in such Act: Provided further, That upon a determination by the Director that funds transferred pursuant to the previous proviso are not necessary for the purposes provided, such amounts may be transferred back to the Account: Provided further, That the transfer authority provided under this heading is in addition to any other transfer authority provided by law.

Summary of Changes

Summary of Changes

**(Dollars in Thousands)**

FY 2023 Enacted
			$2,809,418FY 2024 President's Budget
			$2,825,418Net change
			$16,000FY 2023
			Enacted
			FY 2024 President's
			Budget
			Built-in Change
			from FY 2023 CRCHANGES
			FTEs
			Budget
			Authority
			FTEs
			Budget
			Authority
			FTEs
			Budget
			AuthorityA.  Built-in:
			 1. Intramural research:a. Annualization of January 2023 pay increase & benefits
			
			$72,895
			
			$78,246
			
			$809b. January FY 2024 pay increase & benefits
			
			72,895
			
			78,246
			
			2,794c. Paid days adjustment
			
			72,895
			
			78,246
			
			281d. Differences attributable to change in FTE
			
			72,895
			
			78,246
			
			3,738e. Payment for centrally furnished services
			
			34,745
			
			35,301
			
			556f. Cost of laboratory supplies, materials, other expenses, and non-recurring costs
			
			153,773
			
			126,022
			
			-18,910Subtotal
			
			
			
			
			
			-$10,7322. Research Management and Support:a. Annualization of January 2023 pay increase & benefits
			
			$51,904
			
			$60,705
			
			$574b. January FY 2024 pay increase & benefits
			
			51,904
			
			60,705
			
			1,987c. Paid days adjustment
			
			51,904
			
			60,705
			
			200d. Differences attributable to change in FTE
			
			51,904
			
			60,705
			
			10,495e. Payment for centrally furnished services
			
			358
			
			364
			
			6f. Cost of laboratory supplies, materials, other expenses, and non-recurring costs
			
			45,462
			
			43,827
			
			1,023Subtotal
			
			
			
			
			
			$14,285Subtotal, Built-in
			
			
			
			
			
			$3,553FY 2023 Enacted
			FY 2024 President's
			Budget
			Program Change
			from FY 2023 EnactedCHANGES
			No.
			Amount
			No.
			Amount
			No.
			AmountB.  Program:
			 1.  Research Project Grants:a. Noncompeting
			2,364
			$1,320,070
			2,637
			$1,461,393
			273
			$141,323b. Competing;
			804
			644,074
			881
			528,784
			77
			-115,290c. SBIR/STTR
			127
			90,130
			126
			91,729
			-1
			1,599Subtotal, RPGs
			3,295
			$2,054,274
			3,644
			$2,081,906
			349
			$27,6322. Research Centers
			26
			$32,220
			26
			32,200
			0
			-$203. Other Research
			585
			175,845
			599
			171,534
			14
			-$4,3104. Research Training
			682
			36,051
			697
			38,208
			15
			2,1575. Research and Development Contracts
			134
			151,891
			129
			157,105
			-5
			5,213Subtotal, Extramural
			
			$2,450,281
			
			$2,480,953
			
			$30,6726. Intramural Research
			330
			$261,413
			345
			$239,569
			15
			-$11,1127. Research Management and Support
			302
			97,724
			362
			104,896
			60
			-7,1138. Construction
			
			0
			
			0
			
			09. Buildings and Facilities
			
			0
			
			0
			
			0Subtotal, Program
			632
			$2,809,418
			707
			$2,825,418
			75
			$12,447Total Changes
			
			
			
			
			
			$16,000

Fiscal Year 2024 Budget Graphs

History of Budget Authority and FTE's:




  Image
              Funding Levels by Fiscal Year bar graph (dollars in millions): 2020 - $2,449.7; 2021 - $2,505.9; 2022 - $2,607.2; 2023 - $2,809.4; 2024 - $2,825.4



  Image
              FTEs by fiscal year bar graph: 2020 - 525 FTEs; 2021 - 554 FTEs; 2022 - 601 FTEs; 2023 - 632 FTEs; 2024 - 707 FTEs
Distribution of Mechanism:




  Image
              FY24 Budget Mechanisms: Research Project Grants - $2,081,906 (74%); Intramural Research - $239,569 (8%); Other Research - $171,534 (6%); R&D Contracts - $157,105 (6%); RMS - $104,896 (4%); Research Training - $38,208 (1%); Research Centers - $32,200 (1%)
Change by Selected Mechanism:




  Image
              FY 2024 Estimated Percent Change from FY 2023 Mechanism bar graph
Organization Chart




  Image
              NINDS Organization Chart


Budget Authority by Activity

Budget Authority by Activity1

**(Dollars in Thousands)**

FY 2022
			Final
			FY 2023
			Enacted
			FY 2024
			President's Budget
			FY 2024
			+/-
			FY 2022 EnactedExtramural Research
			Detail:
			FTEs
			Amount
			FTEs
			Amount
			FTEs
			Amount
			FTEs
			AmountDivision of Neuroscience
			
			$1,612,936
			
			$1,755,399
			
			$1,786,427
			
			$31,027Division of Clinical Research
			
			124,982
			
			131,100
			
			131,193
			
			93Division of Translational Research
			
			198,602
			
			208,322
			
			208,469
			
			147Division of Extramural Activities
			
			103,540
			
			108,608
			
			108,685
			
			77Opiod Research2
			
			237,305
			
			246,852
			
			246,180
			
			-$672**Subtotal, Extramural**
			
			**$2,277,365**
			
			**$2,450,281**
			
			**$2,480,953**
			
			**$30,672**Intramural Research
			**321**
			**$233,988**
			**330**
			**$261,413**
			**345**
			**$239,569**
			**15**
			**-$21,844**Research Management & Support
			**280**
			**$95,837**
			**302**
			**$97,724**
			**362**
			**$104,896**
			**60**
			**$7,172**TOTAL
			**601**
			**$2,607,190**
			**632**
			**$2,809,418**
			**707**
			**$2,825,418**
			**75**
			**$16,000**1 Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

2 Total for HEAL Initiative including IR and RMS is (in thousands) $270,295 in FY 2022, $280,295 in FY 2023, and $280,295 in FY 2024.



Justification of Budget Request

Justification of Budget Request
National Institute of Neurological Disorders and Stroke

Authorizing Legislation: Section 301 and Title IV of the Public Health Service Act, as amended.



Budget Authority (BA):

FY 2022
			Final
			FY 2023
			Enacted
			FY 2024
			President's
			Budget
			FY 2024 +/-
			FY 2023BA
			$2,607,190,000
			$2,809,418,000
			$2,825,418,000
			$16,000,000F T E
			601
			632
			707
			75Program funds are allocated as follows: Competitive Grants/Cooperative Agreements; Contracts; Direct Federal/Intramural and Other.

**Overall Budget Policy:** The FY 2024 President’s Budget request for NINDS is $2,825.4 million, an increase of $16.0 million or 0.6 percent compared to the FY 2023 Enacted level level. The NINDS request includes 21st Century Cures Act funding of $86.0 million for the BRAIN Initiative. Funding for the HEAL Initiative is equal to the FY 2023 Enacted level of $280.3 million.

Program Descriptions

Extramural Research

Investigator-initiated research driven by scientific opportunity is the foundation for NINDS extramural research, and specific initiatives focus on topics and public health priorities that warrant a more targeted approach. The NINDS Extramural divisions (Division of Neuroscience, Division of Translational Research, Division of Clinical Research, and Division of Extramural Activities) also support research training, resources, core facilities, and scientific conferences.

Division of Neuroscience (DON)

As the largest part of the NINDS extramural program, DON supports research on the normal brain, spinal cord, and nerves of the body; mechanisms of neurological injury and disease; and early development of treatments and diagnostics. DON also supports research resources, core facilities, and scientific conferences. Investigator-initiated research driven by scientific opportunity is the foundation for the DON portfolio, and specific initiatives focus on topics and public health priorities that warrant a more targeted approach. DON program areas include:

**Basic neuroscience research**:  Gaps in understanding nervous system development and function and disease mechanisms hinder progress in treating and preventing neurological disorders. Basic research to fill those gaps is critical to the NINDS mission and is unlikely to receive sustained support from the private sector. Investing in basic research provides a broad foundation for future breakthroughs. For example, two basic neuroscientists supported by NINDS received the 2021 Nobel Prize in Physiology or Medicine. Over decades of research David Julius and Ardem Patapoutian identified receptors in nerve endings that trigger electrical impulses in response to temperature changes and mechanical force. Beyond unraveling mysteries about how we sense heat, touch, and body position, these fundamental discoveries are leading to new approaches for treating chronic pain and other conditions.
	**Neurodegeneration:** NINDS leads NIH research support for many neurodegenerative diseases. Programs for Parkinson’s disease include the Morris K. Udall Centers of Excellence; the Parkinson’s Disease Biomarkers Program (PDBP); and the Accelerating Medicines Partnership for Parkinson’s Disease (AMP-PD), which leverages patient cohorts and resources from PDBP and other programs to identify biomarkers and new targets for therapies. As part of the National Plan to Address Alzheimer’s Disease, NINDS leads NIH research on Alzheimer’s Disease Related Dementias (ADRD), which include Lewy Body dementia (LBD), frontotemporal dementia, vascular contributions to cognitive impairment and dementia (VCID), and mixed etiology dementias. Co-funding from the National Institute on Aging (NIA) enables support for specific initiatives and an extended payline for meritorious ADRD research proposals. NINDS is also partnering with the NIH Common Fund on the Accelerating Leading-edge Science in ALS (ALS2) initiative, which supported four new projects in 2021 on new mechanistic insights, finding target genes for therapeutic intervention, assessing a way to slow progression, and how environmental exposures contribute to ALS risk.
	**Stroke and cerebrovascular disease:**NINDS supports a broad portfolio of research to understand stroke causes and the mechanisms involved in stroke-related damage and repair, which might be harnessed to aid neuroprotection and recovery. NINDS established the Stroke Preclinical Assessment Network (SPAN) to rigorously test potential neuroprotective therapies in rodent models of acute ischemic stroke, with built-in replication studies across multiple laboratories to ensure unbiased results. Therapies that are successful in SPAN may later move into clinical trials through the NIH StrokeNet, a NINDS-funded network for stroke clinical trials. NINDS stroke research includes studies to understand small vessel disease (SVD) in the brain, which affects the brain’s small arteries and veins. In addition to stroke, SVD is a major cause of VCID. Together with NIA, NINDS also supports a national consortium called MarkVCID to develop and evaluate biomarkers that will help predict, diagnose, and track VCID.
	**Rare diseases**:  Many rare diseases affect the nervous system, and research on these disorders often yields insights into more common diseases with shared mechanisms. NINDS supports a large portfolio of research on rare diseases and is a partner in the NIH Rare Diseases Clinical Research Network, funding consortia for lysosomal disorders, mitochondrial diseases, dystonia, and others. NINDS has contributed to new treatments for rare disorders, including the first gene-based, disease-modifying therapies for spinal muscular atrophy and muscular dystrophy. An ongoing NINDS initiative aims to fill gaps in clinical trial readiness for rare neurological and neuro-muscular diseases with new therapies on the horizon, and a new initiative will support natural history and clinical outcome assessment studies for ultra-rare neurological diseases, meeting a critical need for therapy development. In FY 2023, NINDS will lead NIH support for a data management and coordinating center for the Undiagnosed Disease Network, enabling this successful program to continue past its initial NIH Common Fund support.
	**Other neurological disorders**:  DON research includes studies on many more nervous system disorders and on mechanisms shared across diseases, with studies informing new and improved treatments and diagnostics for hydrocephalus, spinal cord injury, traumatic brain injury (TBI), and neuropathies, among others. NINDS seeks input from research and patient communities to help set priorities, such as the Benchmarks for Epilepsy Research, updated in 2020. Because neuroscience spans scientific disciplines, NINDS also works closely with other NIH Institutes in areas of complementary interest. For example, in addition to having a leading role in the NIH HEAL InitiativeSM, NINDS is the primary NIH Institute for pain and headache research and leads the NIH Pain Consortium, which includes 23 Institutes and Centers. NINDS also leads NIH efforts focused on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), including support for multi-disciplinary research centers focused on understanding this complex disease and building research capacity. Additional areas of collaboration include developmental disorders such as cerebral palsy, autism, Fragile X Syndrome, and Down syndrome; muscular dystrophies; brain tumor; autoimmune conditions such as multiple sclerosis (MS); and infections that affect the nervous system, including acute and long-term effects of COVID-19.**The Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative** The NIH BRAIN Initiative® is an ambitious program to develop and apply new tools and technologies to fundamental questions about the brain and ultimately to inspire new treatments for brain diseases. NINDS and NIMH are lead partners in the NIH BRAIN Initiative, working with eight other Institutes and Centers. With Congressional support, including funding authorized by the 21st Century Cures Act, the BRAIN Initiative has invested over $3 billion in more than 1,300 research projects, engaging scientists from many areas of expertise as well as mathematicians, engineers, physicians in individual labs and interdisciplinary teams. The BRAIN Initiative has also led positive change in the culture of neuroscience research through its emphasis on neuroethics, diversity and inclusion, and promoting infrastructure and practices for sharing research data and tools.

Tools and technologies developed through the BRAIN Initiative are helping researchers understand complex cognitive functions, investigate disease mechanisms, and develop and improve clinical applications.

Over 250 scientists at more than 45 institutions across three continents collaborated in the BRAIN Initiative® Cell Census Network (BICCN), which created an atlas of cell types and a neuronal wiring diagram for the mammalian primary motor cortex.
	Tools developed by the BICCN are aiding new discoveries on cell types that degenerate in Alzheimer’s and Parkinson’s disease, providing clues for future interventions that may one day slow or even halt disease progression.
	New approaches for recording brain activity show how the brain stores and recalls distinct events and how brain circuitry can layer memories of events over more stable memories of spatial environments.
	BRAIN research is fueling advances in adaptive, individualized brain stimulation for movement disorders, epilepsy, chronic pain, obsessive compulsive disorder, and depression, as well as brain-computer devices to aid communication in people who cannot speak.Three large-scale transformative projects will build on progress: The BRAIN Initiative Cell Atlas Network (BICAN), to generate an atlas of human brain cell types across the lifespan; the Armamentarium for Precision Brain Cell Access, to build a toolkit for researchers to access specific cells and circuits in model systems and human tissue specimens; and the BRAIN Initiative Connectivity Across Scales (BRAIN CONNECTS) Network, to grow research and technical capacity to generate wiring diagrams that span entire brains. In addition, BRAIN continues to support projects that shift technology from the bench to clinical settings and projects in new focus areas, including a more complete understanding of the neural circuit basis of behavior.

**Budget Policy:** The FY 2024 President’s Budget request for the Division of Neuroscience is $1,786.4 million, an increase of $31.0 million, or 1.8 percent, from the FY 2023 Enacted level.

Division of Translational Research (DTR)

The DTR leads extramural NINDS therapy development through milestone-driven programs and services that support all development stages for drugs, devices, and biologic therapies, from preclinical studies to first-in-human clinical trials. Translational research is prone to failure and poses risks for private sector investment. DTR programs help to remove these risks by advancing therapies to a point of readiness sufficient for industry interest, or in some cases, for testing in NINDS-funded clinical trials. DTR will support the following programs in FY 2024: .

The **Blueprint Neurotherapeutics Network (BPN),** led by NINDS for the NIH Blueprint for Neuroscience Research, supports small molecule drug development. Recent industry investment in BPN-funded strategies for epilepsy and pain show that this program is helping to bring therapies closer to the clinic. New BPN projects focus on promoting nerve growth after spinal cord injury and preventing post-seizure cognitive deficits.
	The **Innovation Grants to Nurture Initial Translational Efforts (IGNITE)** program funds early-stage therapy development that fuels the pipeline for later stage programs, such as BPN. IGNITE activities include assay validation, demonstrating biological activity sufficient to merit further study, and model system development for early testing.
	The **Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics)** advances biological therapies, including large biological molecules, cell therapies, and gene-targeted therapies. New projects aim to develop treatments for spinal muscular atrophy and for producing on-demand voiding in people with bowel or bladder retention due to spinal cord injury or other diseases. The NINDS Translational Neural Devices program supports therapeutic and diagnostic device development for nervous system disorders, from preclinical studies through early-stage clinical trials. In 2021, NINDS and the NIH Blueprint for Neuroscience Research announced the Blueprint MedTech program as an incubator for cutting-edge neurotechnology.
	The NINDS **Ultra-rare Gene Therapy (URGenT)** Network supports precision medicine therapy development for serious, life-threatening ultra-rare neurological diseases affecting fewer than 20 in one million people. Together, these diseases represent a large medical need without available treatments and with little incentive for private sector therapy development.
	The **NINDS Biomarkers** supports development and validation of biomarkers for use in clinical trials to aid therapy development or to help guide patient care decisions. Projects in advanced validation stages include biomarkers for MS diagnosis and monitoring, TBI prognosis, and differential diagnosis of three different forms of Parkinsonism.
	The **Epilepsy Therapy Screening Program (ETSP)** tests compounds from academic institutions and industry in well characterized models of epilepsy and has contributed to 11 marketed drugs for the treatment of epileptic seizures. The ETSP aims to advance novel therapies to prevent epilepsy, modify disease progression, and treat drug-resistant epilepsy.
	**Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs** support research by small businesses on therapies, diagnostics, and research tools relevant to the NINDS mission. Many DTR programs, as well as the NIH BRAIN® and HEAL® initiatives, include SBIR/STTR components. Among recent successes is a new FDA-cleared product called Nerve Tape® for sutureless repair of injured nerves.
	The new **Office of Neural Exposome and Toxicology (ONETOX)** will focus on the role of non-inheritable factors in neurological diseases, including environmental exposure to toxins, social activity and stress, diet, and the microbiome. ONETOX also oversees the NIH Countermeasures Against Chemical Threats (CounterACT) program, funded by the NIH Office of the Director and part of the Chemical Countermeasures Research Program at the National Institute of Allergy and Infectious Diseases (NIAID)..**Budget Policy:** The FY 2024 President’s Budget request for the Division of Translational Research is $208.5 million, an increase of $0.1 million, or 0.1 percent, from the FY 2023 Enacted level.

Division of Clinical Research (DCR)

DCR supports clinical trials infrastructure and large-scale clinical research, including early and advanced phase clinical trials, comparative effectiveness research, and epidemiological studies for neurological conditions across the lifespan. NINDS clinical research networks provide infrastructure for efficient early and late stage multi-site clinical trials, bring together expert communities to promote high-quality research, enable partnerships with industry and patient groups, and help train future clinical trial investigators. In FY 2024, DCR programs will include:

**NINDS clinical research networks** provide accessible infrastructure for efficient early and late stage clinical trials, bring together expert communities to promote high-quality research, enable partnerships with industry and patient groups, and help train future clinical trial investigators.

The **Network for Excellence in Neuroscience Clinical Trials (NeuroNext)** supports Phase II clinical trials to test investigational treatments prior to larger late-stage trials, as well as studies to discover and validate biomarkers. Since 2011, NeuroNEXT has initiated 11 studies focused on a range of common and rare neurological disorders. Completed trials have built evidence to justify later stage trials for treatments for MS, Huntington’s disease, neuroprotection after acute stroke, and GNE myopathy, a rare muscle disease. A prior biomarker and natural history study on spinal muscular atrophy contributed to the approval of the first treatment for this disease.
	**NIH StrokeNet** supports trials on stroke treatment, prevention, and recovery and rehabilitation through 26 regional centers and over 500 hospitals. Since 2014, the network has conducted 20 trials and contributed to two trials through the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership. Trial results are informing clinical care, including a landmark study showing that surgical removal (endovascular thrombectomy, or EVT) of large vessel blockages can be effective in brain-imaging selected patients up to 16 hours after stroke onset. To assess the potential benefits of expanding this intervention to more patients and to explore innovative methods to augment outcomes and improve systems of care, StrokeNet added a novel EVT Platform in 2022 that will use StrokeNet infrastructure to efficiently and simultaneously test several interventions.
	**Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN),** led by NINDS and the National Heart, Lung, and Blood Institute (NHLBI), conducts clinical trials in emergency care for neurologic, cardiac, respiratory, and hematologic conditions. Ongoing trials are testing treatments for traumatic brain Injury (TBI) and improving neurological outcomes after cardiac arrest in adults, and a new study is addressing cardiac arrest in children. Other new projects are studying EEG patterns and biomarkers for clinical monitoring in patients in a coma after TBI.
	The **Office of Global Health and Health Disparities** within DCR directs NINDS support for research on health disparities for neurological disorders and on minority, community, and global health relevant to the NINDS mission. A new strategic plan for research on health disparities and health equity for neurological disorders will guide and strengthen new NINDS investments.
	The **Prospective Observational Comparative Effectiveness Reearch in Clinical Neurosciences** initiative launched its first study in 2022. Comparing Treatment Approaches to Promote Inpatient Rehabilitation Effectiveness for Traumatic Brain Injury (CARE 4 TBI) will compare specific inpatient rehabilitation approaches for people with TBI to optimize functional outcomes and community participation.
	The **NINDS Common Data Elements (CDE) Program** works with researchers, industry, other Federal agencies, and nonprofit and professional organizations to develop data standards for neurological disorders, to foster collaboration and data sharing across studies, and improve data quality and integrity. The program has developed CDEs for more than 20 disease areas, many with pediatric standards, and a common set for use across diseases. New or updated CDEs are underway for TBI, coma, social determinants of health, and mitochondrial disorders.**Budget Policy:** The FY 2024 President’s Budget request for the Division of Clinical Research is $131.2 million, an increase of $0.1 million, or 0.1 percent, from the FY 2023 Enacted level.

Division of Extramural Activities (DEA)

DEA leads extramural NINDS efforts in research training and career development, workforce diversity, and enhancing research rigor, that together fuel capacity for innovative neuroscience research for generations to come. DEA also houses the NINDS Scientific Review Branch and the Office of Research Operations and Analysis, including grants management and analytical and administrative functions for effective implementation of NINDS programs and policies.

The **Office of Programs to Enhance Neuroscience Workforce Diversity (OPEN)** promotes diversity in neuroscience research via programs designed to overcome barriers to participation and inclusion of underrepresented or disadvantaged groups and individuals with disabilities.10 Programs span career stages from K-12 outreach to mentoring networks and initiatives targeting career transitions, including the NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award supporting diverse graduate students transitioning to postdoctoral work. Among new programs, NINDS partners with six other ICOs on a funding opportunity to enhance the diversity of independent investigators supported through Research Project Grants (R01).The **Office of Training and Workforce Development** directs NINDS extramural research training and career development, including fellowships, mentored awards, and programs at academic institutions. NINDS initiatives complement NIH-wide programs to address unique training needs across neuroscience research career stages and include national research training programs for neurosurgeons and pediatric neurologists, career development awards for advanced trainees launching independent projects, and workshops focused on strengthening mentorship in neuroscience research. In collaboration with OPEN, the NIH Neuroscience Doctoral Readiness Program (DR. Program)11 will support postbaccalaureate research experiences for a diverse cadre of students who have not had access to substantive research opportunities, with a goal to enable successful transition into strong, research-focused doctoral degree programs in biomedical fields.The **Office of Research Quality** promotes rigor and transparency in neuroscience research and has been instrumental to NIH and research journal policies to improve rigor in experimental design and transparent reporting in publications. New initiatives12 support community-driven development of innovative educational materials that will be incorporated into an openly accessible online resource to promote awareness, understanding, and practice of fundamental principles of rigorous research for scientists in various career stages and learning environments.**Budget Policy:** The FY 2024 President’s Budget request for the Division of Extramural Activities is $108.7 million, an increase of $0.1 million, or 0.1 percent, from the FY 2023 Enacted level.

_______________________________________________

10  NINDS Diversity Awards

11  RFA-NS-22-035

12  RFA-NS-21-033; RFA-NS-21-009

NIH Helping to End Addiction Long-termSM (HEAL) Initiative

The NIH HEAL Initiative is a trans-agency effort to speed scientific solutions to stem the national opioid crisis. As the NIH lead for pain research, NINDS HEAL Initiative activities focus on developing non-addictive and effective pain treatments that may mitigate the need for opioids for pain management. NINDS also supports HEAL programs for research training and career development to promote a diverse, dedicated workforce to address evolving opioid and pain public health challenges. NINDS HEAL efforts13 include other NIH ICOs as partners, and they build on and integrate with NINDS programs for basic, translational, and clinical research.

A suite of milestone-driven programs, including the Pain Therapeutic Development Program (PTDP), support the discovery, optimization, and development of non-addictive small molecule and biologic therapies to treat pain. In addition, the Preclinical Screening Platform for Pain (PSPP) tests and characterizes promising non-addictive therapeutic candidates submitted by researchers (small molecules, biologics, or natural products) in animal models that mimic a variety of human pain conditions. Parallel programs support the development of device-based approaches for treating pain and improving pain management. NINDS also leads a HEAL Initiative® program to support the development of biomarkers that can predict or monitor response to pain therapeutics, which will facilitate clinical trials to test new therapies.

The Early Phase Pain Investigation Network (EPPIC-Net) provides infrastructure for the rapid design and performance of Phase II clinical trials to test novel and promising therapeutics for pain, as well as phenotyping and biomarker studies in people with specific pain conditions. EPPIC-Net has launched one clinical trial for knee osteoarthritis pain and will launch two trials for diabetic peripheral neuropathy. NINDS also plays a lead role in the Pain Management Effectiveness Research Network, which supports clinical trials on the comparative effectiveness of existing pharmacological and non-pharmacological therapies for pain management while mitigating the use of opioids. Furthermore, NINDS is a key partner in HEAL efforts to reduce health equities in pain care, with studies to develop, test, and implement interventions to improve outcomes and access to quality pain care in populations that experience health disparities.

**Budget Policy:** The FY 2024 President’s Budget request for NINDS HEAL is $280.3 million, equal to the FY 2023 Enacted level. NINDS HEAL funding for FY 2024 includes $246.2 million for extramural research, $20.0 million for intramural research, and $14.1 million for RMS.

_______________________________________________

13  NINDS Diversity Awards

Intramural Research Program (IRP)

The NINDS IRP conducts research and research training on the NIH campus, spanning basic, translational, and clinical research in neuroscience, neurology, and neurosurgery and hosting state-of-the-art core facilities. The IRP’s unique resources enable innovative, multidisciplinary studies to answer fundamental questions about the nervous system and its diseases; and with over 150 neuroscience research labs from NINDS and 10 other Institutes, including many co-located in the Porter Neuroscience Research Center, the IRP is a rich environment for collaboration.

NINDS investigators recently described novel imaging approaches for monitoring microbleeds due to viral infections in the brain. This research advances our understanding of infections and immune responses in the brain and may aid the development of immune-based therapies for brain infections and cancers.14 In another study, researchers reported a new type of interaction between cholinergic and dopaminergic signaling, two neurotransmitter systems in the brain. The findings have implications for understanding normal cognitive functions such as reward, motivation, and motor learning, as well as in disorders such as Parkinson’s disease.15

NINDS intramural clinical studies benefit from the NIH Clinical Center, a hospital devoted solely to clinical research, and from collaboration with local hospitals and extramural scientists. NINDS leads a multisystem study on post-infectious ME/CFS to identify clinical and biological markers and disease mechanisms, a study of veterans with Gulf War Illness (with the Veterans Health Administration), and a study of people with persistent symptoms after acute COVID-19 infection. Other clinical studies focus on stroke and VCID, neurodegenerative diseases, MS, TBI, epilepsy, brain tumors, movement disorders, and rare genetic disorders, and include early trials for drugs, devices, and gene therapy. In addition, NINDS helps find causes of puzzling neurological cases through the NIH Undiagnosed Diseases Program.

The Roy Blunt Center for Alzheimer’s and Related Dementias (CARD),16 established by NIA and NINDS in 2020, will stimulate ambitious research that may be challenging within traditional extramural mechanisms. Understanding the many ways genes linked to neurodegeneration affect cellular pathways will be essential for finding strategies to prevent or halt disease. CARD is using cutting-edge genetic methods to create a freely available research repository of induced pluripotent stem cell lines modeling over 100 different AD/ADRD gene variants. Among other projects, CARD scientists are also developing a therapeutic strategy designed to clear cellular aggregates of the protein Tau, a pathological hallmark of Alzheimer’s and related dementias.

**Budget Policy:** The FY 2024 President’s Budget request for the Intramural Research Program is $239.6 million, a decrease of $21.8 million, or 8.4 percent, from the FY 2023 Enacted level.

_______________________________________________

14  Early detection of cerebrovascular pathology and protective antiviral immunity by MRI

15  Synaptic-like axo-axonal transmission from striatal cholinergic interneurons onto dopaminergic fibers

16  NIH Intramural Center for Alzheimer’s and Related Dementias (CARD)

Research Management and Support (RMS)

RMS comprises administrative, budgetary, logistical, and scientific support in the review, award, and monitoring of research grants, training awards, and research contracts. RMS also includes strategic planning, program evaluation, regulatory compliance, enhanced patient and community engagement activities, internal DEIA efforts, communication about neurological disorders and NINDS research, and liaison with other agencies, Congress, and the public. In 2021, NINDS updated its stroke prevention campaign (Mind Your Risks), based on evidence linking high blood pressure (hypertension) and the risk of dementia later in life. Updated messaging aims to engage young Black men, to help address high risks for stroke and dementia in Black Americans.

**Budget Policy:** The FY 2024 President’s Budget request for Research Management and Support is $104.9 million, an increase of $7.2 million, or 7.3 percent, from the FY 2023 Enacted level.

Appropriations History

Fiscal Year
			Budget Estimate to Congress
			House Allowance
			Senate Allowance
			Appropriation2015
			$1,608,461,000
			
			
			$1,605,205,000Rescission
			
			
			
			$02016
			$1,660,375,000
			$1,656,334,000
			$1,694,758,000
			$1,696,139,000Rescission
			
			
			
			$020171
			$1,695,180,000
			$1,751,049,000
			$1,803,306,000
			$1,783,654,000Rescission
			
			
			
			$020182
			$1,355,998,000
			$1,853,011,000
			$1,904,666,000
			$2,188,149,000Rescission
			
			
			
			$020192
			$1,838,556,000
			$2,228,780,000
			$2,275,580,000
			$2,274,413,000Rescission
			
			
			
			$020202
			$2,026,031,000
			$2,385,571,000
			$2,490,494,000
			$2,444,687,000Recission
			
			
			
			$020212
			$2,245,110,000
			$2,465,110,00
			$2,526,245,000
			$2,513,393,000Recission
			
			
			
			$020222
			$2,783,300,000
			$2,799,515,000
			$2,786,096,000
			$2,611,370,000Recission
			
			
			
			$020232
			$2,768,043,000
			$2,833,590,000
			$2,765,918,000
			$2,813,925,000Recission
			
			
			
			$020232
			$2,825,418,0001 Budget Estimates to Congress includes mandatory financing.

2 Includes funds derived by transfer from the NIH Innovation Account under the 21st Century Cures Act.

Authorizing Legislation

PHS Act/
			Other Citation
			U.S. Code
			Citation
			2023 Amount
			Authorized
			FY 2023
			Enacted
			2024 Amount
			Authorized
			F Y 2024
			President's BudgetResearch and Investigation
			Section 301
			42§241
			Indefinite
			$2,809,418,000
			Indefinite
			$2,825,418,000National Institute of
			Neurological Disorders and Stroke
			Section 401(a)
			42§281
			Indefinite
			
			IndefiniteTotal, Budget Authority
			
			
			
			$2,809,418,000
			
			$2,825,418,000Amounts Available for Obligation

Amounts Available for Obligation 1

**(Dollars in Thousands)**

Source of Funding
			FY 2022
			Final
			FY 2023
			Enacted
			FY 2024
			President's BudgetAppropriation2
			$2,611,370
			$2,813,925
			$2,825,418OAR HIV/AIDS Transfers
			-$4,180
			-$4,507
			$0Subtotal, adjusted budget authority
			$2,607,190
			$2,809,418
			$2,825,418Unobligated balance, start of year
			$21,103
			$33,120
			$0Unobligated balance, end of year (carryover)3
			-$33,120
			$0
			$0Subtotal, adjusted budget authority
			**$2,595,173**
			**2,842,538**
			**2,825,418**Unobligated balance lapsing
			-$10
			$0
			$0Total obligations
			$2,595,163
			$2,842,538
			$2,825,4181 Excludes the following amounts (in thousands) for reimbursable activities carried out by this account:
FY 2022 - $27,981    FY 2023 - $30,978    FY 2024 - $32,000

2 Of which $76.0 million in FY 2022, $225.0 million in FY 2023, and $86.0 million in FY 2024 is derived by transfer from the NIH Innovation Account under the 21st Century Cures Act.

3 Reflects 21st Century Cures Act funding not obligated in FY 2022, and carried over into FY 2023.

Budget Authority by Object Class

Budget Authority by Object Class 1

**(Dollars in Thousands)**

FY 2023
			Enacted
			FY 2024
			President's Budget
			FY 2024 +/-
			FY 2023Total compensable workyears:Full-time equivalent
			632
			707
			75Full-time equivalent of overtime and holiday hours
			0
			0
			0Average ES salary
			$184
			$184
			$1Average GM/GS grade
			12.9
			12.9
			0.0Average GM/GS salary
			$130
			$138
			$7Average salary, Commissioned Corps (42 U.S.C. 207)
			$0
			$0
			$0Average salary of ungraded positions *(in whole dollars)*
			$146
			$148
			$2OBJECT CLASSES
			FY 2023
			Enacted
			FY 2024
			President's Budget
			FY 2024+/-
			FY 2023Personnel Compensation:11.1 Full-time permanent
			$47,202
			$53,970
			$6,76811.3 Other than full-time permanent
			30,746
			33,473
			2,72611.5 Other personnel compensation
			3,598
			4,001
			40311.7 Military personnel
			164
			177
			1311.8 Special Personnel Services Payments
			12,214
			12,880
			666**11.9 Subtotal Personnel Compensation**
			**$95,181**
			**$104,501**
			**$10,577**12.1 Civilian Personnel benefits
			30,820
			34,392
			3,57212.2 Military Personnel Benefits
			54
			58
			413.0 Benefits to Former Personnel
			0
			0
			0**Subtotal, Pay Costs**
			**$124,798**
			**$138,951**
			**$14,153**21.0 Travel and Transportation of Persons
			2,247
			2,301
			5422.0 Transportation of Things
			379
			388
			923.1 Rental Payments to GSA
			0
			0
			023.2 Rental Payments to Others
			56
			57
			123.3 Communications, Utilities and Miscellaneous Charges
			257
			263
			624.0 Printing & Reproduction
			0
			0
			025.1 Consulting Services
			52,670
			53,569
			89925.2 Other Services
			56,311
			53,462
			-2,84925.3 Purchase of goods and services from government accounts
			191,996
			193,141
			1,14625.4 Operation & Maintenance of Facilities
			697
			707
			1025.5 R&D Contracts
			40,625
			34,051
			6,57425.6 Medical Care
			290
			302
			1225.7 Operation & Maintenance of Equipment
			4,420
			4,084
			-33725.8 Subsistence & Support of Persons
			0
			0
			0**25.0 Subtotal Other Contractual Services**
			**$347,008**
			**$339,316**
			**-$7,693**26.0 Supplies & Materials
			$17,490
			$12,672
			$4,81831.0 Equipment
			26,859
			6,034
			-20,82532.0 Land and Structures
			1,538
			1,575
			3733.0 Investments & Loans
			0
			0
			041.0 Grants, Subsidies & Contributions
			2,288,773
			2,323,849
			35,07642.0 Insurance Claims & Indemnities
			0
			0
			043.0 Interest & Dividends
			12
			12
			044.0 Refunds
			0
			0
			0**Subtotal Non-Pay Costs**
			**$2,684,620**
			**$2,686,467**
			**$1,847****Total Budget Authority by Object Class**
			**$2,809,418**
			**$2,825,418**
			**$16,000**1Includes FTEs whose payroll obligations are supported by the NIH Common Fund.

Salaries and Expenses

Salaries and Expenses

**(Dollars in Thousands)**

OBJECT CLASSES
			FY 2023
			Enacted
			FY 2024
			President's Budget
			FY 2024 +/-
			FY 2023Personnel Compensation:Full-Time Permanent (11.1)
			$47,202
			$53,970
			$6,768Other Than Full-Time Permanent (11.3)
			30,746
			33,473
			2,726Other Personnel Compensation (11.5)
			3,598
			4,001
			403Military Personnel (11.7)
			164
			177
			13Special Personnel Services Payments (11.8)
			12,214
			12,880
			666Subtotal Personnel Compensation (11.9)
			**$93,924**
			**$104,501**
			**$10,577**Civilian Personnel Benefits (12.1)
			$30,820
			$34,392
			$3,572Military Personnel Benefits (12.2)
			54
			58
			4Benefits to Former Personnel (13.0)
			0
			0
			0Subtotal Pay Costs
			**$124,798**
			**$138,951**
			**$14,153**Travel & Transportation of Persons (21.0)
			$2,247
			$2,301
			$54Transportation of Things (22.0)
			379
			388
			9Rental Payments to Others (23.2)
			56
			57
			1Communications, Utilities and Misc. Charges (23.3)
			257
			263
			6Printing and Reproduction (24.0)
			0
			0
			0Other Contractual Services:Consultant Services (25.1)
			52,400
			53,292
			893Other Services (25.2)
			56,311
			53,462
			2,849Purchases from government accounts (25.3)
			103,473
			102,880
			-593Operation and Maintenance of Facilities (25.4)
			697
			707
			10Operation and Maintenance of Equipment (25.7)
			4,420
			4,084
			-337Subsistence and Support of Persons (25.8)
			0
			0
			0Subtotal Other Contractual Services
			**$217,301**
			**$214,425**
			**-$2,876**Supplies and Materials (26.0)
			$17,490
			$12,672
			-$4,818Subtotal Non-Pay Costs
			**$237,729**
			**$230,106**
			**-$7,623**Total Administrative Costs
			**$362,527**
			**$369,057**
			**$6,530**Detail of Full-Time Equivalent Employment (FTE's)

Detail of Full-Time Equivalent Employment (FTE's)

OFFICE/DIVISION
			FY 2022
			Final
			FY 2023
			Enacted
			FY 2024
			President's BudgetCivilian
			Military
			Total
			Civilian
			Military
			Total
			Civilian
			Military
			TotalOffice of the DirectorDirect:
			76
			-
			76
			70
			-
			70
			85
			-
			85Reimbursable:
			7
			-
			7
			14
			-
			14
			16
			-
			16Total:
			**83**
			**-**
			**83**
			84
			
			**84**
			**101**
			**-**
			**101**Division of Clinical ResearchDirect:
			24
			-
			24
			27
			-
			27
			32
			-
			32Reimbursable:
			-
			-
			-
			1
			-
			1
			2
			-
			2Total:
			**24**
			**-**
			**24**
			**28**
			**-**
			**28**
			**34**
			**-**
			**34**Division of Translational ResearchDirect:
			32
			-
			32
			45
			-
			45
			56
			-
			56Reimbursable:
			4
			-
			4
			4
			-
			4
			4
			-
			4Total:
			**36**
			**-**
			**36**
			**49**
			**-**
			**49**
			**60**
			**-**
			**60**Division of Intramural ResearchDirect:
			304
			1
			305
			312
			-
			312
			328
			-
			328Reimbursable:
			16
			-
			16
			18
			-
			18
			17
			-
			17Total:
			**320**
			**1**
			**321**
			**330**
			**-**
			**330**
			**345**
			**-**
			**345**Division of Extramural ActivitiesDirect:
			80
			-
			80
			80
			-
			80
			95
			-
			95Reimbursable:
			-
			-
			-
			-
			-
			-
			1
			-
			1Total:
			**80**
			**-**
			**80**
			**80**
			**-**
			**80**
			**96**
			**-**
			**96**Division of NeuroscienceDirect:
			50
			-
			50
			50
			-
			50
			59
			-
			59Reimbursable:
			7
			-
			7
			11
			-
			11
			12
			-
			12Total:
			**57**
			**-**
			**57**
			**61**
			**-**
			**61**
			**71**
			**-**
			**71**Total
			**600**
			**1**
			**601**
			**632**
			**-**
			**632**
			**707**
			**-**
			**707**Includes FTEs whose payroll obligations are supported by the NIH Common Fund.FTEs supported by funds from Cooperative Research and Development Agreements
			0
			0
			0
			0
			0
			0
			0
			0
			0

FTEs supported by funds from Cooperative Research and Development Agreements.

FISCAL YEAR
			Average GS Grade2020
			12.62021
			13.82022
			12.82023
			12.92024
			12.9Detail of Positions

Detail of Positions1

***(Dollars in Thousands)***

GRADE
			FY 2022 Final
			FY 2023
			Enacted
			FY 2024
			President's BudgetTotal, ES Positions
			1
			1
			1Total, ES Salary
			182,850
			183,500
			184,152GM/GS-15
			66
			66
			66GM/GS-14
			99
			107
			116GM/GS-13
			134
			144
			157GS-12
			70
			75
			82GS-11
			34
			34
			34GS-10
			1
			1
			1GS-9
			13
			13
			13GS-8
			3
			3
			3GS-7
			5
			5
			5GS-6
			1
			1
			1GS-5
			1
			1
			1GS-4
			2
			2
			2GS-3
			2
			2
			2GS-2
			1
			1
			1GS-1
			0
			0
			0Subtotal
			**432**
			**455**
			**484**Commissioned Corps (42 U.S.C. 207):Assistant Surgeon General
			0
			0
			0Director Grade
			1
			0
			0Senior Grade
			0
			0
			0Full Grade
			1
			0
			0Senior Assistant Grade
			0
			0
			0Assistant Grade
			0
			0
			0**Subtotal**
			**2**
			**0**
			**0**Ungraded
			224
			233
			242Total permanent positions
			433
			449
			499Total positions, end of year
			659
			689
			727Total full-time equivalent (F T E) employment, end of year
			601
			632
			707Average ES salary
			182,850
			183,500
			184,152Average GM/GS grade
			12.8
			12.9
			12.9Average GM/GS salary
			125,752
			130,458
			137,5731 Includes FTEs whose payroll obligations are supported by the NIH Common Fund. About NINDS
  
    

    Who We Are
                                                              
                    
                                      Staff Directory
    
            Program Directors
    
            Advisory Council
                                                              
                    
                                      NANDSC ME/CFS Research Roadmap Working Group
    
            NANDS Council Neural Exposome Top Priorities (NEXT) Working Group
    
            NANDSC Membership Roster
    
            NANDSC Fundamental Neuroscience Working Group
    
            NANDSC Working Group for Health Disparities and Inequities in Neurological DisordersLeadership
    
            Board of Scientific Counselors
    
            Director's Corner
    
            Organization
                                                              
                    
                                      Office of the Director
                                                              
                    
                                      Division of Clinical Research
    
            Division of Extramural Activities
    
            Division of Intramural Research
    
            Division of Neuroscience
    
            Division of Translational Research
    
            Office of Scientific Management and Operations
                                                              
                    
                                      Office of Management
    
            Office of Neuroscience Communications and Engagement
    
            Office of Pain Policy and Planning
    
            Office of Science Policy and PlanningOffice of the BRAIN Director
        
  
              
        
  
              
        
  
              
    
            What We Do
                                                              
                    
                                      NINDS Mission
    
            Strategic Plans & Evaluations
                                                              
                    
                                      Strategic Plans
                                                              
                    
                                      Strategic Plan 2021-2026
    
            Alzheimer’s Disease-Related Dementias Summits
    
            Amyotrophic Lateral Sclerosis (ALS)
    
            Cerebral Palsy Research
    
            Epilepsy Research
    
            Health Disparities and Health Equity
    
            Muscular Dystrophy Coordinating Committee
    
            Parkinson’s Disease Research Planning
    
            Stroke Research Planning
    
            Tuberous Sclerosis Complex
    
            Workforce DiversityProgram Evaluations
        
  
              
    
            Workforce Diversity
                                                              
                    
                                      Diversity Policies & Resources
    
            Enhancing DiversityImpact
                                                              
                    
                                      NINDS Contributions to Approved Therapies
    
            Translational Research Success Stories
    
            Workforce Diversity Success Stories
                                                              
                    
                                      Success Stories: Ukpong Eyo
    
            Success Stories: Brielle Ferguson
    
            Success Stories: Audrey Winkelsas
    
            Success Stories: Eduardo Candelario-Jalil
    
            Success Stories: Daniel Colón-Ramos
    
            Success Stories: Julia Dallman
    
            Success Stories: Rachel Dreilinger
    
            Success Stories: Michelle Gray
    
            Success Stories: Corey Harwell
    
            Success Stories: Franck Kalume
    
            Success Stories: Zayd Khaliq
    
            Success Stories: Naomi Lee
    
            Success Stories: Joaquin N. Lugo
    
            Success Stories: Susan Marino
    
            Success Stories: Cassie S. Mitchell
    
            Success Stories: Edjah K. Nduom
    
            Success Stories: Ketema Paul
    
            Success Stories: Azizi Seixas
    
            Success Stories: Alexis Simpkins
    
            Success Stories: Catrina Sims-Robinson
    
            Success Stories: Mariana Torrente
    
            Success Stories: Tyisha WilliamsBudget & Legislation
                                                              
                    
                                      FY23 Total Appropriation
    
            FY22 Total Appropriation
    
            FY21 Total Appropriation
    
            FY20 Total Appropriation
    
            NINDS Annual Budget
                                                              
                    
                                      NINDS 2025 Congressional Budget Justification
    
            NINDS 2024 Congressional Budget Justification
    
            NINDS 2023 Congressional Budget Justification
    
            NINDS 2022 Congressional Budget Justification
    
            NINDS 2021 Congressional Budget JustificationLegislative Updates
        
  
              
    
            Scientific Review Branch
        
  
              
    
            Job Opportunities
                                                              
                    
                                      Careers at NINDS
                                                              
                    
                                      Director, Biologics Neurotherapeutic Development
    
            Health Program Specialist
    
            Health Scientist Administrator (Program Officer)
    
            Health Scientist Administrator (Program Director), Neural Environment Cluster
    
            Neurosurgery Research Fellowships
    
            Program Director, Parkinson’s Disease
    
            Program Director, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
    
            Staff Clinician, Section of Infections of the Nervous SystemNIH BRAIN Initiative® Careers
    
            NIH HEAL Initiative Careers
                                                              
                    
                                      Health Scientist Administrator, PTDP
    
            Health Scientist Administrators, NINDS/PSPP

Did you find the content you were looking for?
  Yes, I did find the content I was looking for



No, I did not find the content I was looking forPlease rate how easy it was to navigate the NINDS website
  Very easy to navigate



Easy to navigate



Neutral



Difficult to navigate



Very difficult to navigateThank you for letting us know! Any other feedback?Submit

This site is protected by reCAPTCHA and the Google Privacy Policyand Terms of Serviceapply.

      Last reviewed on July 10, 2023
        Contact Us
  

        
              Contact NINDS
                Visitor Information
        Related Sites
  

        
              Site Map
                National Institutes of Health
                Department of Health & Human Services
                USA.gov
        Policies
  

        
              Accessibility
                Freedom of Information Act
                Linking Policy
                Privacy Statement
                Vulnerability Disclosure Policy
Follow NINDS On Social Media
          
          National Institutes of Health (NIH)
          9000 Rockville Pike, Bethesda, MD, 20892